Search Results - off-the-shelf

15 Results

Sort By:

Biopolymer Encapsulation Increases the Bioavailability and Efficacy of D-PDMP in Interfering with Atherosclerosis and Cardiac Hypertrophy in apoE-/- Transgenic Mice

INVENTION NOVELTYA novel glycolipid inhibitor anti-atherosclerosis drug compound able to enhancegastro-intestinal absorption and residence time to reduce and ameliorateeffects of arteriosclerosis VALUE PROPOSITIONDespite great success of statins (cholesterol reducing agents), little is known aboutother molecules such as glycolipids that also rise with...

Published: 5/9/2024 | Inventor(s): Subroto Chatterjee

Keywords(s): Antagonists/Inhibitors, Cardiovascular Diseases, Disease Indication, Drug Delivery Vehicle, Non-novel, Off-the-shelf, Polymers, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities

Farnesylation of PARIS Prevents Dopaminergic Neurodegeneration in Models of Parkinson’s Disease

Unmet Need: Parkinson's disease (PD) is an incurable progressive neurodegenerative disease. It is characterized clinically by motor dysfunction that is due to the preferential loss of dopaminergic neurons in the brain. Current treatment strategies for PD are mainly limited to the management of the motor symptoms with drugs such as L-DOPA or dopamine...

Published: 5/9/2024 | Inventor(s): Ted Dawson, Valina Dawson, Joo-Ho Shin, Yunjong Lee, Areum Jo

Keywords(s): Agonists/Promoters, CNS and Neurological Disorders, Disease Indication, Non-novel, Off-the-shelf, Parkinson's Disease, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Parkinson's Disease

M4N and Temozolomide Combination Therapy for Glioblastoma multiforme (GBM)

Unmet NeedGlioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults and remains one of the most aggressive types of malignancies. The mainstay of GBM treatment is surgery, radiation and adjuvant chemotherapy using temozolomide (TMZ). While treatment options have incrementally improved, survival rates remains dismal. Only...

Published: 5/9/2024 | Inventor(s): Ru Chih Huang, Jong ho Chun, Yu-Ling Lin, Yu-Chuan Liang, Kuang-Wen Liao, Tiffany Jackson, David Mold, Chien-Hsien Lai

Keywords(s): Agonists/Promoters, Brain Cancer, Cancers, Chemotherapy/Immunotherapy, Combination, Disease Indication, Glioblastoma, Glioma, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology > Brain Cancer

Targeting liver nuclear receptors as a treatment for Wilsons disease

Wilson disease is a hepato-neurologic disorder caused by mutations in the gene ATP7B and accumulation of copper in tissues, predominantly in the liver. The disease is lethal, unless treated. Current life-long treatment involves copper chelation or copper replacement using Zn. Both procedures alleviate major symptoms but side effects are frequent and...

Published: 5/9/2024 | Inventor(s): Svetlana Lutsenko, James Hamilton

Keywords(s): Agonists/Promoters, Biomarker, Disease Indication, Genetic Disorders, Liver, Liver Transplant, Mechanism-of-action Biomarker, Non-novel, Off-the-shelf, Predicted Novelty, Single, Small Molecules, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Transplants, Wilson's Disease

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Genetic Diseases > Wilson's Disease, Clinical and Disease Specializations > Rare Diseases, Clinical and Disease Specializations > Transplantation > Liver Transplant, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Genetic Diseases, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Transplantation

Imaging Bacteria with Light-emitting Substrates of Thymidine Kinase

The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative...

Published: 5/17/2024 | Inventor(s): Catherine Foss, Bert Vogelstein, Shibin Zhou, Kenneth Kinzler, Chetan Bettegowda, Martin Pomper

Keywords(s): Discovery/Research Tools, Labels/Markers, Non-novel, Off-the-shelf, Predicted Novelty, Research Reagent, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Diagnostics > Diagnostic Imaging, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities

Glutaminase Inhibitor Discovery and Nanoparticle-Enhanced Delivery for Cancer Therapy

Glutaminase Inhibitor Discovery and Nanoparticle-Enhanced Delivery for cancer therapyJHU REF: C13142 Invention novelty: An improved glutaminase (GLS) inhibitors delivery system to enhance efficacy and prolong glutaminase inhibitor drug levels in tumor for improve treatment of pancreatic cancer. Value Proposition: Currently available glutaminase inhibitors...

Published: 5/9/2024 | Inventor(s): Barbara Slusher, Jie Fu, Justin Hanes, Qingguo Xu, Quy Hoa Le Thi, Takashi Tsukamoto

Keywords(s): Adenocarcinoma, Antagonists/Inhibitors, Cancers, Disease Indication, Drug Delivery Vehicle, Nanoparticles, Non-novel, Off-the-shelf, Pancreatic Cancer, Pancreatic ductal adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Adenocarcinoma, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Clinical and Disease Specializations > Oncology > Pancreatic Ductal Adenocarcinoma, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

Novel Triazole Compounds to Treat Nav1.6-related Brain Disorders

Unmet NeedAbnormal behavior of sodium (Nav) channels is linked to a variety of epilepsy syndromes, movement disorders, and neuropathic pain. While researchers continue to elucidate the roles of different Nav channel isoforms within a variety of neurological disorders, current therapeutics influence numerous Nav channel isoforms, resulting in off-target...

Published: 5/9/2024 | Inventor(s): Frank Bosmans, Dimpy Kalia

Keywords(s): Antagonists/Inhibitors, CNS and Neurological Disorders, Disease Indication, Epilepsy, Neuropathy, Non-novel, Novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Neuropathy, Clinical and Disease Specializations > Neurology > Epilepsy

Emetine for Inhibition of Human Cytomegalovirus (HCMV)

UNMET NEED: Infection with human cytomegalovirus (HCMV) continues to be a major threat for pregnant women and immunocompromised hosts. Although anti-HCMV therapies are available, development of new agents are desired because of the limited drugs approved for HCMV, the side effects associated with them, and the emergence of resistant viral mutants during...

Published: 5/9/2024 | Inventor(s): Ravit Boger, Marc Ferrer, Juan Marugan, Andres Garcia, Noel Southall, Xin Hu

Keywords(s): Antagonists/Inhibitors, Cytomegalovirus, Disease Indication, Infectious Diseases, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Viral Infections

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases > Cytomegalovirus, Clinical and Disease Specializations > Infectious Diseases > Viral Infections, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities

Ethoxyquin and Derivatives for Treatment of Peripheral Neuropathies and Other Neurodegenerative Disorders

Peripheral neuropathies are a group of neurodegenerative disorders affecting the peripheral nerves. Currently there is no effective therapy that prevents nerve degeneration except in cases of autoimmune peripheral neuropathies. Wehave now identified a compound, ethoxyquin (EQ), that prevents nerve degeneration in chemotherapy-induced peripheral neuropathy...

Published: 5/9/2024 | Inventor(s): Weiran Chen, Jing Zhu, Ahmet Hoke

Keywords(s): CNS and Neurological Disorders, Disease Indication, Neuropathy, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology > Neuropathy, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities

Rapid Induction of Human Cancer Cell Death by Synergistic Treatment of Tetra-O-Methyl Nordihydroguaiaretic Acid (M4N, Terameprocol) with 7-Hydroxystaurosporine (UCN-01)

Value Proposition: Tetra-O-methyl nordihydroguaiaretic acid (M4N, EM1421, Terameprocol), a novel transcription inhibitor, is an effective anticancer agent with excellent safety profile (Smolewski, P. Idrugs 11, 204-214, 2008). In the current study, we report an enhancement of anticancer activities of M4N in combination with 7-hydroxystaurosporine (UCN-01),...

Published: 5/9/2024 | Inventor(s): Kotohiko Kimura, Ru Chih Huang

Keywords(s): Antagonists/Inhibitors, Cancers, Combination, Disease Indication, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Targeted Therapy/Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities

1 2